Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 47
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
7/18/2007
 
First Published:
2/1/2002
1.
Phase IV Randomized Study of Filgrastim (G-CSF) or Pegfilgrastim as Secondary Prophylaxis Versus Conservative Management of Chemotherapy-Induced Neutropenia for Maintenance of Chemotherapy in Women With Early Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Supportive care
Closed
18 and over
Other
ACCOG-SCTN-BR0101
SCTN-BR0101, EU-20143, NCT00030758
Last Modified:
5/9/2007
 
First Published:
5/1/2000
2.
Phase III Pilot Randomized Study of Filgrastim-SD/01 Versus Filgrastim (G-CSF) With Concurrent Chemotherapy in Patients With Newly Diagnosed Sarcoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Closed
25 and under at diagnosis
NCI
NCI-00-C-0092G
AMGEN-20000124, NCT00020137
Last Modified:
11/29/2007
 
First Published:
7/1/2000
3.
Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Not specified
NCI
GOG-0184
ECOG-G0184, RTOG-EN0130, NCT00006011, GOG-0184
Last Modified:
5/29/2008
 
First Published:
10/25/2003
4.
Phase III Randomized Study of Paclitaxel, Ifosfamide, and Cisplatin Versus Vinblastine, Ifosfamide, and Cisplatin as Second-Line Therapy in Men With Progressive or Recurrent Metastatic Germ Cell Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI
CALGB-90106
CALGB-90106, NCT00072215
Last Modified:
12/18/2006
 
First Published:
5/23/2005
5.
Phase III Randomized Study of Neoadjuvant Cisplatin and Docetaxel With Versus Without Thoracic Conformal Radiotherapy Followed By Surgical Resection and Docetaxel in Patients With Newly Diagnosed Favorable Prognosis Stage IIIA Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI
RTOG-0412
SWOG-S0332, RTOG-0412-SWOG-S0332, CALGB-RTOG-0412, ECOG-RTOG-0412, NCCTG-RTOG-0412, NCT00113386
Last Modified:
5/7/2007
 
First Published:
1/28/2007
6.
Phase III Randomized Study of Adjuvant Therapy Comprising Epirubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With Versus Without Fluorouracil and/or Pegfilgrastim in Women With Node-Positive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 70
Other
GIM-2
EU-20681, NCT00433420
Last Modified:
7/7/2008
 
First Published:
6/23/2003
7.
Phase II Study of Oblimersen in Combination With Doxorubicin and Docetaxel in Patients With Metastatic or Locally Advanced Breast Cancer (Phase I portion of the study completed as of 8/16/04)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
NCI
MDA-DM-02700
NCI-6023, NCT00063934, 6023
Last Modified:
5/24/2008
 
First Published:
1/23/2004
8.
Phase II Study of Induction Chemotherapy Comprising Doxorubicin and Cisplatin Followed By Combretastatin A4 Phosphate and Radiotherapy in Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer (Phase I portion of the study closed as of 5/6/04)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
NCI, Pharmaceutical / Industry
CASE-CWRU-3302
CWRU-040337, OXIGENE-CWRU-3302, NCT00077103, CASE-3302
Last Modified:
1/2/2008
 
First Published:
6/23/2004
9.
Phase I/II Study of Oblimersen in Combination With Rituximab, Ifosfamide, Carboplatin, and Etoposide in Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
NCI
UCCRC-12975A
6243, NCI-6243, NCT00086944
Last Modified:
8/2/2006
 
First Published:
9/16/2005
10.
Phase I/II Study of Erlotinib in Combination With Docetaxel and Carboplatin as Front-Line Therapy Followed by Maintenance Therapy With Erlotinib in Patients With Newly Diagnosed Stage III or IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
PSOC-2001
AVENTIS-PSOC-2001, PSOC-IRB-5689, NCT00217529
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute